masld glp 1 Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists Resmetirom and GLP-1 agonists for
Description
Multiple endocrine neoplasia type 2
Conclusions By analyzing the FAERS data, we outlined the association between hypoglycemia and different GLP-1RAs in greater detail in terms of clinical features, onset, and outcomes
Currently, two ongoing clinical trials are investigating the role of GLP-1 RAs in IBD management, that would lead to further knowledge: a French study (ID NCT05196958) evaluating the safety and efficacy of GLP-1 RAs in treatment of DM2 in overweight IBD patients (115), and an American study (ID NCT06774079) comparing the efficacy of GLP-1 RAs tirzepatide versus diet in CD patients (116)
Manufacturer savings programs can significantly reduce costs, but they come with important limitations: Novo Nordisk offers savings cards that can reduce copays to as little as $25 per month, but critically, these cannot be used without insurance coverage
No genetic result replaces clinical judgment or emergency medical evaluation
Clean ingredients, no fillers finally something that delivers on the GLP-1 support promises
